For Immediate Release
August 30, 2016
Ton Shen Health
Ton Shen Health/Life Rising Corporation of Chicago, IL, is expanding its recall of “DHZC-2” Tablets to all lots purchased before August 24, 2016 because they have the potential to be contaminated with elevated levels of lead.
The recalled "DHZC-2" tablets were sold nationwide in retails stores and distributed through mail orders.
The product comes in a 1.6 ounce bottle, UPC: 616042102727
The FDA is currently investigating 6 cases of adverse effects involving individuals taking DHZC-2 supplement tablets.
The potential for contamination was noted after FDA notice of higher level of lead presence in DHZC-2 samples from lot # 2163-844.
What is Lead?
Lead is a toxic substance present in our environment in small amounts and everyone is exposed to some lead from daily actions such as inhaling dust, eating food, or drinking water. In general, the small exposure to lead within the U.S. population does not pose a significant public health concern. However, exposure to larger amounts of lead can cause lead poisoning.
What are the Symptoms of Lead Exposure?
While lead can affect nearly every bodily system, its effects depend upon the amount and duration of lead exposure and age. Exposure to extremely high amounts of lead may result in overt and possibly severe symptoms for which an individual is likely to seek medical attention. However, infants, young children and the developing fetus can be affected by chronic exposure to amounts of lead that may not result in obvious symptoms of lead poisoning. A child with lead poisoning may not look or act sick. Lead poisoning in children has been linked to:
- learning disabilities
- developmental delays
- lower IQ scores
The sale of DHZC-2 tablets has been suspended and inventory put on hold while FDA and the company continue to investigate the source of the problem.
Consumers who have purchased DHZC-2 tablets are urged to return them to the place of purchase for a full refund or dispose of them. Consumers with questions may contact the company at 1-312-842-2775 central standard time, Monday to Friday, from 9:30AM to 5:00PM. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178 .